Basilea Pharmaceutica AG BASILEA .../ CH0011432447 /
2024-05-23 5:03:47 PM | Chg. +1.49 | Volume | Bid2024-05-23 | Ask2024-05-23 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
44.35CHF | +3.49% | 1,268 Turnover: 56,059.55 |
-Bid Size: - | -Ask Size: - | 578.36 mill.CHF | - | 50.75 |
GlobeNewswire
05-21
Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipelin...
GlobeNewswire
05-16
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone paym...
GlobeNewswire
05-14
NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 f...
GlobeNewswire
05-03
Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024
GlobeNewswire
04-24
NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results
GlobeNewswire
04-24
Basilea shareholders approve all proposals of the board of directors at the annual general meeting
GlobeNewswire
04-17
Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules
GlobeNewswire
04-09
Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics
GlobeNewswire
04-04
Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indicati...
GlobeNewswire
04-02
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for t...
GlobeNewswire
03-11
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers mile...
GlobeNewswire
02-13
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors
GlobeNewswire
02-13
Basilea reports strong 2023 full-year results with profitability significantly above guidance, whils...
GlobeNewswire
01-29
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Pha...
GlobeNewswire
01-19
Cresemba® sales in Latin America trigger first sales milestone payment to Basilea
GlobeNewswire
2023-12-26
Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China ...
GlobeNewswire
2023-12-26
LianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian Markets
GlobeNewswire
2023-12-11
Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the Unit...
GlobeNewswire
2023-12-07
Santhera Appoints Executive Committee Members as it Transitions into Commercial Stage
GlobeNewswire
2023-12-04
Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovat...